Transplant-free Ph-positive ALL for MRD-negative adults
If a pill plus immunotherapy makes the leukaemia undetectable, can most adults safely skip a bone-marrow transplant?
Half of D-ALBA patients were not transplanted and did well; MD Anderson ponatinib-blinatumomab cohorts report ~85% 3-year OS with few transplants. Randomised confirmation is needed, especially for IKZF1-plus genotypes.
Pages like this
not linked directly; found by shared links- PairingBCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)
Shares D-ALBA (GIMEMA LAL2116), Ponatinib, Ph-positive ALL, Dasatinib.
- TrialPhALLCON
Shares Ponatinib, Ph-positive ALL, MRD-negative complete remission, Acute lymphoblastic leukaemia.
- IdeaMRD-guided transplant decisions in intermediate-risk AML
Shares NGS-based MRD (clonoSEQ and molecular MRD), MRD-negative complete remission, Allogeneic stem cell transplantation.
- TermPhiladelphia chromosome (Ph+, BCR::ABL1)
Shares Ponatinib, Dasatinib, Blinatumomab, Acute lymphoblastic leukaemia.
- TargetBCR::ABL1 (Philadelphia chromosome)
Shares D-ALBA (GIMEMA LAL2116), Ponatinib, Ph-positive ALL, Dasatinib.
- InstitutionGIMEMA
Shares D-ALBA (GIMEMA LAL2116), Blinatumomab, Acute lymphoblastic leukaemia.
- TrialECOG-ACRIN E1910
Shares MRD-negative complete remission, Blinatumomab, Acute lymphoblastic leukaemia.
- TrialTOWER